Brind.

Tandem Diabetes Care stock was downgraded to Sell on July 10, 2025, following an analyst report from Citibank.

2 reports, 1 independent Updated Jul 10

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Tandem Diabetes Care stock was downgraded to Sell on July 10, 2025, following an analyst report from Citibank.

Who's involved

What this event is mainly about

Tandem Diabetes Care, Inc.Citibank

Keep exploring

The entities involved

Tandem Diabetes Care, Inc.
U.S. healthcare company
- Tandem Mobi utilizes Dexcom G7 technology for monitoring.Mon 09:18
- Solventum and Tandem Diabetes Care, Inc., two companies in the healthcare sector, are currently facing market comparison.Sun 18:43
Citibank
American multinational bank
- Citi maintained a Buy rating on Entegris stock, while Entegris announced R&D spending related to the Trump Administration.Sun 01:54

Coverage

Newest first; wire copies grouped

Jul 10StockStoryWhy Tandem Diabetes (TNDM) Shares Are Sliding Today Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) fell 3.5% in the morning session after a Citi analyst downgraded the stock
Jul 9Unknown outlet